Common heartburn drugs may harm your kidneys: study

Image
Press Trust of India New York
Last Updated : Oct 28 2015 | 4:57 PM IST
Certain common medications used to treat heartburn and acid reflux may have damaging effects on the kidneys, researchers including one of Indian-origin have found.
The drugs, proton pump inhibitors (PPIs), are among the top 10 class of prescribed medications in the US.
The prevalence of chronic kidney disease (CKD) is on the rise, with more than 20 million Americans burdened by the disease, researchers said.
Diabetes and hypertension are common risk factors for CKD; however, certain medications can also play a role.
Two new studies show that increased use of proton pump inhibitors (PPIs), medications that treat reflux and stomach ulcers, may be contributing to the CKD epidemic.
In one study, Benjamin Lazarus of Johns Hopkins University and his colleagues followed 10,482 adults with normal kidney function from 1996 to 2011.
They found that PPI users were between 20 per cent and 50 per cent more likely to develop CKD than non-PPI users, even after accounting for baseline differences between users and non-users.
This discovery was replicated in a second study, in which over 240,000 patients were followed from 1997 to 2014.
"In both studies, people who used a different class of medications to suppress stomach acid, known as H2-blockers, did not have a higher risk of developing kidney disease," said Lazarus.
"If we know the potential adverse effects of PPI medications we can design better interventions to reduce overuse," he said.
In another study, Pradeep Arora of State University of New York and his team found that among 24,149 patients who developed CKD between 2001 and 2008 (out of a total of 71,516 patients), 25.7 per cent were treated with PPIs.
Among the total group of patients, those who took PPIs were less likely to have vascular disease, cancer, diabetes, hypertension, and chronic obstructive pulmonary disease, but PPI use was linked with a 10 per cent increased risk of CKD and a 76 per cent increased risk of dying prematurely.
"As a large number of patients are being treated with PPIs, health care providers need to be better educated about the potential side effects of these drugs, such as CKD," said Arora.
"PPIs are often prescribed outside of their approved uses, and it has been estimated that up to two-thirds of all people on PPIs do not have a verified indication for the drug," he said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 28 2015 | 4:57 PM IST

Next Story